New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2013
12:39 EDTSGYPSynergy Pharmaceuticals price target raised to $13 from $7 at Cantor
Cantor increased its target on Synergy after the company reported results from a Phase III trial of its chronic constipation treatment, plecanatide, that the firm views as positive. The firm increased its E.U. and Japanese sales estimates for the drug, and it sees the company as a takeover target. Cantor believes that Synergy has multiple upcoming positive catalysts and it maintains a Buy rating.
News For SGYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
10:45 EDTSGYPSynergy discussing possible sale with advisers, Bloomberg reports
Subscribe for More Information
10:18 EDTSGYPHigh option volume stocks
High option volume stocks: BTX ALL FIVE SGYP SWFT RHT IDCC NVS WGO XBI
10:06 EDTSGYPSynergy Pharmaceuticals talking to advisers about possible sale, Bloomberg says
March 16, 2015
18:21 EDTSGYPSynergy Pharmaceuticals reports Q4 EPS (32c), consensus (28c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use